Tuesday, March 18, 2025 | 12:58 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Cadila Healthcare completes phase-2 trial of Hepatitis C drug for Covid-19

95% subjects in the test who received a single dose of PegiHepTM along with SOC became virus free as assessed by RT-PCR on day 14, compared to 68% of those who only received SOC

Cadila Healthcare, Moraiya
Premium

File photo of a Cadila Healthcare facility

Vinay Umarji Ahmedabad
Cadila Healthcare Ltd., also known as Zydus Cadila, on Thursday announced "successful" completion of phase two clinical trial of its biological therapy Pegylated Interferon alpha-2b, ‘PegiHepTM’ on Covid-19 patients. 
 
In what now paves the way for phase three trials in India, Cadila said that the open-label, randomized, comparator controlled study was

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in